10-K: Precision BioSciences Refocuses on In Vivo Gene Editing, Outlines Strategic Priorities in 10-K Filing

Precision BioSciences' 10-K filing highlights a strategic shift towards in vivo gene editing, divesting its CAR T platform and focusing on its ARCUS technology for genetic and infectious diseases.

Summary

• Precision BioSciences' 10-K filing details the company's strategic refocus on in vivo gene editing, leveraging its ARCUS platform.
• The company divested its ex vivo allogeneic CAR T candidate, azercabtagene zapreleucel (azer-cel), to Imugene and granted a license to TG Therapeutics for non-oncology applications of azer-cel.
• Precision is now concentrating on its wholly-owned in vivo programs, PBGENE-HBV for chronic hepatitis B and PBGENE-PMM for mitochondrial myopathy, with IND/CTA submissions expected in 2024 and 2025, respectively.
• The company continues collaborations with Novartis for hemoglobinopathies and Prevail Therapeutics for Duchenne muscular dystrophy and other targets.
• Precision's ARCUS technology is highlighted for its unique properties, including a staggered cut that promotes homology directed repair (HDR), small size for versatile delivery, and single-component simplicity.
• The company reported a net loss of $61.3 million for the year ended December 31, 2023, and has an accumulated deficit of $489.6 million.
• As of December 31, 2023, the company had 109 full-time employees, with 78 in research and development and 29 holding Ph.D. or M.D. degrees.
• The company believes its current cash and cash equivalents, expected operational receipts, and availability of its ATM facility will be sufficient to fund operations into the second half of 2026.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the strategic refocus and potential of the ARCUS platform are positive, the company's financial losses, dependence on external funding, and competitive landscape temper the overall sentiment. The company is making strategic moves, but faces significant challenges.

Positives

• The strategic shift towards in vivo gene editing aligns with the growing potential of this therapeutic approach.
• Divestment of the CAR T platform and licensing agreements provide upfront capital and potential future revenue streams.
• The ARCUS platform's unique properties offer a competitive advantage in the gene editing field.
• The company has a strong intellectual property portfolio with multiple issued and pending patents.
• The company has a clear path to clinical trials for its lead in vivo programs.
• The company has a strong team with extensive experience in gene therapies.

Negatives

• The company has incurred significant operating losses and does not expect to be profitable in the foreseeable future.
• The company has a limited operating history, making it difficult to evaluate its future prospects.
• The company is heavily dependent on the successful development of its ARCUS technology.
• The company faces significant competition in the rapidly evolving gene editing field.
• The company will need substantial additional funding to advance its programs.
• The company is subject to various risks and uncertainties, including those related to clinical trials, regulatory approvals, and manufacturing.

Risks

• The company may not be able to achieve or maintain profitability.
• The company may not be able to raise sufficient capital when needed.
• The company's product candidates may not be safe or effective.
• The company may face significant competition from other companies in the gene editing field.
• The company may experience delays in clinical trials or regulatory approvals.
• The company may experience manufacturing problems.
• The company may be subject to product liability lawsuits.
• The company may not be able to obtain or maintain intellectual property protection for its technology.
• The company may be subject to adverse public perception of genome editing technology.

Future Outlook

The company expects its current cash and cash equivalents, expected operational receipts, and availability of its ATM facility will be sufficient to fund operations into the second half of 2026 and to achieve first-in-human Phase 1 clinical data for its lead in vivo gene editing programs.

Management Comments

• The company is dedicated to improving life through genome editing.
• The company's goal is to broadly translate the potential of genome editing into permanent genetic solutions for significant unmet medical needs.
• The company is focused on progressing its gene editing portfolio and differentiating ARCUS as a unique tool in the gene editing field.

Industry Context

The announcement reflects a broader trend in the biotechnology industry towards gene editing and gene therapy, with companies focusing on developing innovative treatments for genetic and infectious diseases. The divestment of the CAR T platform and focus on in vivo gene editing is a strategic move to concentrate on core competencies and potentially more lucrative areas of the market.

Comparison to Industry Standards

• Precision BioSciences competes with companies like Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Prime Medicine, Tune Therapeutics, and Verve Therapeutics in the genome editing space.
• Many of these competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than Precision BioSciences.
• Precision BioSciences' ARCUS technology is differentiated by its unique cut, small size, and single-component nature, which may offer advantages over other gene editing technologies like CRISPR-Cas9.
• The company's focus on in vivo gene editing aligns with a growing trend in the industry, but it also faces competition from companies developing gene therapy treatments.
• The company's financial results are typical for a clinical-stage biotechnology company, with significant operating losses and a reliance on external funding.

Stakeholder Impact

• Shareholders will experience dilution from potential future equity raises.
• Employees will be affected by the strategic shift and potential changes in operations.
• Customers and patients may benefit from the development of new gene editing therapies.
• Suppliers and manufacturers may be affected by changes in the company's supply chain.
• Creditors may be affected by the company's financial performance and ability to repay debt.

Next Steps

• Submit an IND/CTA for PBGENE-HBV in 2024.
• Submit an IND/CTA for PBGENE-PMM in 2025.
• Continue development of partnered programs with Novartis and Prevail.
• Continue to evaluate the ARCUS platform with regards to safety, on-target editing, gene insertion, complex gene edits, and compatibility with viral and non-viral delivery.

Key Dates

Keywords

in vivo gene editing, ARCUS platform, gene therapy, hepatitis B, mitochondrial myopathy, Duchenne muscular dystrophy, hemoglobinopathies, clinical trials, biotechnology, intellectual property